Medtronic Raises 2027 Forecasts Amid Surge in Heart Device Demand

Medtronic has revised its fiscal 2027 financial forecasts upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant announced an increase in its revenue growth outlook and adjusted profit forecast, reflecting confidence in its expanding product portfolio and market presence.

Revised Financial Projections

The company increased the lower end of its adjusted per-share profit forecast for fiscal 2027 to $5.94, up from $5.90, while maintaining the upper end at $6. Additionally, Medtronic now anticipates annual organic revenue growth between 7.25% and 7.75%, an improvement from the previous projection of 6.75% to 7.25%.

According to CEO Geoff Martha, the company’s confidence stems not only from quarterly performance but also from the broad strength across its business units and the growing contributions from new growth platforms.

Strategic Investments in Heart Devices and Robotics

Medtronic is also making significant investments to bolster its product offerings. The company announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire it for $210 million. Furthermore, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in several markets outside the U.S.

Martha highlighted the untapped potential in emerging markets, noting that the penetration of soft tissue robotic surgery remains below 1%. The integration of Cornerstone's Sentire device complements Medtronic's existing Hugo platform, providing a comprehensive suite of solutions for hospitals worldwide.

Cardiovascular Segment Performance

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was fueled by an 88% increase in sales from its pulsed field ablation portfolio, a technology used to treat irregular heart rhythms.

The company’s adjusted quarterly per-share profit stood at $1.45 on revenue of $9.76 billion, surpassing analysts' estimates of $1.39 per share on $9.55 billion in revenue, according to data compiled by LSEG.

Medtronic's CFO Thierry Pieton mentioned that the company received tariff refunds nearly covering duties paid during the quarter. However, these refunds have not been factored into future financial projections.

Martha emphasized Medtronic's strategic focus on high-growth segments within the medtech industry, ensuring the company is well-positioned to meet the needs of large patient populations and maintain its competitive edge.